SCHEMBL7032450

SCHEMBL7032450

O=Cn1c(=O)[nH]c(=O)c2cc(C(=O)OCc3ccccc3)sc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.41
MMP2 P08253 3/20 0.40
MMP12 P39900 3/20 0.40
MMP9 P14780 2/20 0.40
MMP1 P03956 2/20 0.40
KDM4E B2RXH2 1/20 0.38
KMT2A Q03164 2/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
ESR1 P03372 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6237834 0.84 HSD17B10 (0.45) MMP13MMP2MMP12MMP9MMP1
SCHEMBL6257382 0.83 BRD4 (0.48) MMP13MMP2MMP12MMP9MMP1
SCHEMBL6468536 0.82 MMP13 (0.42) MMP13MMP2MMP12MMP9MMP1
SCHEMBL7104043 0.75 MMP2 (0.45) MMP13MMP2MMP12MMP9MMP1
SCHEMBL6261894 0.74 KDM4E (0.41) KDM4EKMT2AMAPK1ESR1HSD17B10
SCHEMBL6258644 0.71 MMP13 (0.54) MMP13MMP2MMP12MMP9MMP1
SCHEMBL6472987 0.70 HSD17B10 (0.48) MMP13MMP2MMP12MMP9MMP1
SCHEMBL7145713 0.70 MMP13 (0.43) MMP13MMP2MMP12MMP9MMP1
SCHEMBL13269161 0.69 TDP1 (0.51) MMP13MMP2MMP12MMP9MMP1
SCHEMBL6237897 0.69 KDM4E (0.45) MMP2MMP12MMP9MMP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 MMP13 1/4885MMP2 16/4885MMP12 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.